BRIEF-Lantern Pharma Reports Complete Response In Heavily Pre-Treated Lymphoma Patient In Phase 1 Clinical Trial

Reuters
Jul 23
BRIEF-<a href="https://laohu8.com/S/LTRN">Lantern Pharma</a> Reports Complete Response In Heavily Pre-Treated Lymphoma Patient In Phase 1 Clinical Trial

July 23 (Reuters) - Lantern Pharma Inc LTRN.O:

  • LANTERN PHARMA REPORTS COMPLETE RESPONSE IN HEAVILY PRE-TREATED LYMPHOMA PATIENT WITH LP-284 IN PHASE 1 CLINICAL TRIAL

Source text: ID:nBw4G23GLa

Further company coverage: LTRN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10